A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Rilotumumab (Primary) ; Capecitabine; Cisplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RILOMET-2
  • Sponsors Amgen
  • Most Recent Events

    • 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
    • 19 Feb 2015 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Nov 2014 Status changed from recruiting to discontinued, according to an Amgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top